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Abstract
α2-Macroglobulin (α2M) and haptoglobin (Hp) are both abundant secreted glycoproteins that are best
known for their protease trapping and hemoglobin binding activities, respectively. Like the small heat
shock proteins, both these glycoproteins have in common the ability to protect a range of proteins from
stress-induced amorphous aggregation and have been described as extracellular chaperones. Using an
array of biophysical techniques, this study establishes that in vitro at substoichiometric levels and under
physiological conditions α2M and Hp both inhibit the formation of amyloid fibrils from a range of proteins.
We also provide evidence that both α2M and Hp interact with prefibrillar species to maintain the solubility
of amyloidogenic proteins. These findings suggest that both α2M and Hp are likely to play an important
role in controlling the inappropriate aggregation of proteins in the extracellular environment.
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α 2-Macroglobulin (α 2M) and haptoglobin (Hp)
are both abundant secreted glycoproteins that
are best known for their protease trapping and
hemoglobin binding activities, respectively.
Like the small heat shock proteins, both these
glycoproteins have in common the ability to
protect a range of proteins from stress-induced
amorphous aggregation and have been
described as extracellular chaperones. Using an
array of biophysical techniques, this study
establishes that in vitro, at substoichiometric
levels and under physiological conditions, α 2M
and Hp both inhibit the formation of amyloid
fibrils from a range of proteins. We also
provide evidence that both α 2M and Hp
interact with prefibrillar species to maintain
the solubility of amyloidogenic proteins. These
findings suggest that both α 2M and Hp are
likely to play an important role in controlling
the inappropriate aggregation of proteins in the
extracellular environment.
The pathology of more than 40 human
degenerative diseases is associated with the
deposition of proteinaceous fibrils or plaques
commonly known as amyloid (1). These protein
deposition diseases affect many of the tissues and
organs of the human body and are comprised of

various sporadic and occasionally familial
amyloidogenic disorders, e.g. Alzheimer’s (AD)
and Parkinson’s (PD) diseases, a number of
transmissible
prion-based
disorders
(e.g.
Creutzfeldt-Jakob disease), and non-neuropathic
disorders such as Type II diabetes and systemic
lysozyme amyloidosis. Amyloid formation in vitro
is now recognized as a common phenomenon and
follows a kinetic pathway characteristic of
crystallization; there is an initial ‘lag’ or
nucleation phase, followed by a rapid exponential
‘growth’ or polymerization phase (2), and finally a
plateau phase in which no further fibril growth
occurs. The lag phase is usually agreed to
represent the time required for the formation of
soluble (prefibrillar) oligomers or nuclei that are
required to seed fibril growth.
It has been proposed that proteins are able to
aggregate and form amyloid deposits in vivo when
the normally efficient protein quality control
machinery is overwhelmed (3). As a consequence,
a great deal of current research is focused on the
protein quality control machinery and the role it
plays in these disorders (4). However, in many
cases, the disease-associated protein deposits are
located in the extracellular environment outside
the reach of the well-studied intracellular protein

1

quality control machinery. Molecular chaperones
are central components of the intracellular protein
control system and it is only recently that the
existence of extracellular counterparts to these
species has been proposed (5). One such
extracellular chaperone, clusterin, has been shown
to potently inhibit amyloid formation when it is
present during the early stages of the fibrilforming process (6-9). Clusterin appears not to
bind to the native form of the substrates tested, nor
does it detectably bind to mature fibrils.
Interestingly, binding to some species important
for the nucleation event was observed to result in
inhibition of fibril formation (8,9). Recently, two
other secreted glycoproteins, haptoglobin (Hp) and
α2-macroglobulin (α2M), have been shown to have
chaperone activity similar to that of clusterin and
to suppress the amorphous aggregation of a range
of unrelated proteins (10,11). The role of these
abundant extracellular chaperones in the formation
of amyloid deposits in vivo is currently unknown
but is of great interest in the context of
understanding the triggers of amyloid diseases.
α2M is an abundant human blood glycoprotein,
comprised of ~10% carbohydrate by mass (12). It
is best known for its ability to inhibit a broad
range of proteases. Upon interaction with a
protease, α2M undergoes limited proteolysis in a
region containing a variety of protease cleavage
sites (known as the bait region) leading to a major
conformational change that results in the physical
trapping of the protease within a steric “cage”
(13). The trapped protease forms a covalent
linkage with α2M by reacting with an
intramolecular thiol ester bond to yield a
conformationally altered form known as
“activated” or “fast” α2M (α2M*). Activated α2M
exposes a receptor recognition site for low density
lipoprotein receptor related protein (LRP) (13).
Small nucleophiles such as methylamine can also
activate α2M by directly interacting with the thiol
ester bond (14).
Aside from its interactions with proteases, α2M
binds to a wide range of ligands, including those
associated with protein deposition disorders.
Example of ligands include Aβ peptide (15), prion
protein (16) and β2-microglobulin (17), which are
strongly linked with Alzheimer’s disease, the

spongiform encephalopathies and dialysis related
amyloidosis, respectively. In addition, α2M binds
to cytokines and growth factors (18), and to a
range of hydrophobic structures including
endotoxin, phenyl-Sepharose, and liposomes (19).
Binding to hydrophobic molecules does not inhibit
the trapping of proteases and is not known to be
associated with any conformational changes (19).
In accord with that discussed above, α2M is found
associated with amyloid deposits in AD and
spongiform encephalopathies (16,20). Previous
work has indicated that α2M can inhibit the
formation of amyloid fibrils by Aβ peptide (6) and
protect cells from Aβ toxicity in an LRP
dependent fashion (21). It was recently shown that
α2M has a promiscuous ATP-independent
chaperone action (11). It forms stable complexes
with misfolded proteins and maintains their
solubility but is unable to affect their refolding
independently (11). Whether α2M can inhibit
amyloid formation by peptides and proteins other
than Aβ has not been tested.
Hp is a secreted acidic glycoprotein produced
mainly in the liver and found in most bodily fluids
of humans and other mammals. The levels of Hp
in human plasma are increased up to 8-fold during
various physiological stresses (e.g. inflammation),
leading to it being described as an "acute phase
protein" (12,22). In humans, a cross-over event is
thought to have produced two principal alleles
(Hp1 and Hp2), which results in individuals
expressing one of three major Hp phenotypes (Hp
1-1, Hp 2-1, Hp 2-2). In its simplest form (Hp 11), Hp exists in a disulfide-linked (α1β)2 structure
with a molecular weight of ~100 kDa. However, in
Hp 2-1 and Hp 2-2, an additional cysteine residue
in the α2 chain allows the formation of a series of
disulfide-linked αβ polymers (~100 to ~500 kDa).
Hp is best known for its high affinity binding to
hemoglobin (Hb) (KD ~ 10-15 M) (12). Formation
of the Hp-Hb complex inhibits Hb-mediated
generation of lipid peroxides and hydroxyl
radicals, which are thought to occur in areas of
inflammation (22). When complexed to Hb, Hp is
known to be recognized by the cell surface
receptors CD163 and Mac-1 and to be taken up by
receptor-mediated endocytosis for degradation
(23). Hp has also been implicated in immune
regulation (24) and shown to inhibit cathepsin B
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activity (25). Taken together, the available
evidence indicates that Hp is likely to play an
important role in suppressing the inflammatory
response under a variety of different conditions.
Human Hp specifically inhibits the precipitation of
a wide variety of proteins induced by a range of
stresses (10,26). Like clusterin, Hp forms stable
and soluble high molecular weight complexes with
misfolded proteins, but has no independent ability
to refold misfolded proteins. Immunoaffinity
depletion of Hp from human serum significantly
increases the amount of protein that is precipitated
in response to stresses (10). Thus, Hp has the
ability to protect many different proteins from
stress-induced amorphous precipitation and its
effects in whole human serum suggest that this
activity is likely to be relevant in vivo. Currently,
there are no published studies of the effects of Hp
on amyloid formation, although Hp is found
associated with Aβ amyloid deposits in vivo (27).
The aims of this study were to determine if α2M
and Hp could affect the in vitro formation of
amyloid aggregates by a range of unrelated
proteins and, if so, to characterize the
mechanism(s) involved. We selected three
amyloid forming proteins that are linked to disease
(Aβ1-42, calcitonin, and lysozyme which are
associated with Alzheimer’s disease, a localized
amyloidosis and a familial systemic amyloidosis,
respectively) (1) and one other system, a designed
peptide with no connections with disease (peptide
ccβw).
EXPERMENTAL PROCEDURES
Materials
α2M and Hp (phenotype 2-1) were purified from
human plasma obtained from Wollongong
Hospital (Wollongong, NSW, Australia) as
previously described (10,11). The concentration of
Hp was determined by absorbance at 280 nm using
the molar extinction coefficient of 5.1 x 104
(corresponding to a 50 kDa αβ dimer) (28). α2M
concentrations were determined using an
extinction coefficient of 8.93 for a 1% solution
(corresponding to a 720 kDa tetramer) (19).
Thioflavin T (Thio T), bicinchoninic acid (BCA)

micro
protein
assay
reagent,
hexafluoroisopropanol (HFIP), and bovine serum
albumin (BSA) were purchased from Sigma (MO,
USA). Calcitonin (Calc) and the short coiled-coil
β (ccβw) peptide, which transforms from a helical
conformation at 20 oC into amyloid fibrils at 37 oC
(9), were purchased from Auspep (Melbourne,
Australia). Aβ1-42 was purchased from Biopeptide
(San Diego, CA, USA), resuspended in HFIP and
divided into aliquots in which the solvent was left
to evaporate, resulting in a peptide ‘film’ that was
frozen at - 80 oC. The non-natural variant of
human lysozyme, I59T, was expressed and
purified as described (29). The monoclonal antiAβ
antibody
WO2
(hybridoma
culture
supernatant) was a kind gift from Dr Kevin
Barnham (Department of Pathology, University of
Melbourne, Australia).
Fibril formation in vitro
Immediately before use, Aβ1-42 was resuspended in
buffer (2 parts 20 mM NaOH, diluted in 7 parts
Milli Q water and 1 part 10X phosphate buffered
saline (PBS; 137 mM NaCl, 2.7 mM KCl, 1.5 mM
KH2PO4, and 8 mM Na2HPO4, pH 7.5)) and was
centrifuged at 13,000 g for 10 minutes to remove
any aggregated material. Aβ1-42 (10 µM) was
shaken at 600 rpm for 8 h at 37 oC in PBS
supplemented with 0.9 mM CaCl2, 0.5 mM MgCl2,
100 µM CuCl2, and 600 µM glycine (PBSCu).
ccβW (60 µM) and Calc (150 µM) were shaken at
600 rpm for 300 min at 37 oC in 0.1 M Na2HPO4,
pH 7.8, and 50 mM Na2HPO4, pH 7.4,
respectively. Fibril formation by Aβ, ccβw and
Calc, in the presence or absence of either Hp or
α2M, was measured in situ by Thio T fluorescence
(see below) using a FLUOstar OPTIMA
fluorescence plate reader (BMG Labtech,
Australia). Variant human lysozyme (I59T) (6.8
µM in 0.1 M sodium citrate buffer, pH 5.0) was
incubated at 60 °C in a stirred 1 ml cuvette, and
light-scattering monitored at 500 nm (5 nm slit
width) using a Cary Eclipse spectrofluorimeter
(Varian Ltd., Oxford UK); the stirred cuvette was
found to give more reproducible I59T aggregation
than incubation in multiwell plates. Furthermore,
co-incubation of Thio T with protein mixtures
containing I59T was found to affect the rate of
protein aggregation, thus Thio T analyses were
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performed only at the endpoint of each assay (see
below). Molar concentrations were calculated
using the monomeric molecular masses of the
amyloid forming peptides, and masses of 720 kDa
for the α2M tetramer and 50 kDa for Hp (based on
the αβ dimer). To confirm that Hp and α2M do not
themselves form Thio T reactive aggregates under
the conditions used, each protein (at 1.0-12.5 µM)
was treated as described above and the Thio T
fluorescence then measured.
Effects of hemoglobin binding on the ability of
Hp to inhibit amyloid formation
To generate Hp–hemoglobin (Hb) complexes (HpHb), Hp (15 µM) was incubated with Hb in PBS in
an equimolar ratio for 2 h at room temperature. To
form amyloid, 10 µM Aβ1-42 was shaken at 600
rpm for 8 h at 37 oC in PBSCu; 60 µM ccβW was
shaken at 600 rpm for 300 min at 37 oC in PBS.
Fibril formation in the presence or absence of
either Hp or Hp-Hb, was measured as in situ Thio
T fluorescence (see below) using a FLUOstar
OPTIMA fluorescence plate reader (BMG
Labtech, Australia). Molar ratios of 1:20 Hp:Aβ
and 1:30 Hp:ccβw were used as these ratios did not
completely prevent aggregation and any effects,
positive or negative, on chaperone action could be
determined. To confirm that Hb alone did not
affect the formation of Thio T reactive aggregates
under the conditions used, Hb alone at the same
final concentration was added to reactions as
described above and the Thio T fluorescence then
measured.
Thioflavin T fluorescence assays
Thio T (50 µM) was added to aggregation
mixtures of Aβ1-42, ccβW, or Calc and the
fluorescence measured at intervals using a
FLUOstar OPTIMA fluorescence plate reader with
440 nm excitation (10 nm slit-width) and 490 nm
emission (10 nm slit width). In the case of I59T,
only the endpoint Thio T fluorescence was
measured using a Cary Eclipse spectrofluorimeter
with 440 nm excitation (slit-width 10 nm) and an
emission scan from 450–600 nm (slit-width 10
nm).

Effects of α 2M and Hp on mature amyloid
fibrils
Amyloid fibrils were formed using conditions
outlined above. At the conclusion of in vitro fibril
formation time courses, α2M or Hp were added to
give molar ratios of α2M/Hp:Aβ = 1:10,
α2M/Hp:Calc = 1:15, and α2M/Hp:ccβw = 1:15,
and incubated for a period of 500 min at 37oC. The
samples were subsequently analysed using Thio T
fluorescence (as described above) and then
centrifuged for 30 min at 10,000 g. The
supernatant was removed and the pellet
resuspended and washed repeatedly in PBS.
Insoluble material was then redissolved in DMSO
before being diluted 10 fold in PBS. A BCA micro
protein assay was conducted (as per the
manufacturer's instructions) to quantify the protein
content of the resulting samples.
Transmission electron microscopy (TEM)
Endpoint samples of aggregation reactions
incubated as outlined above, in the presence or
absence of α2M or Hp (at molar ratios of
α2M/Hp:Aβ/I59T = 1:10 or α2M/Hp:ccβw/Calc =
1:15), were applied to Formvar and carbon-coated
nickel electron microscopy grids and stained with
uranyl acetate (2% (w/v), Agar Scientific, UK). A
Philips CM100 transmission electron microscope
(FEI Company, USA) was used to view samples
under a magnification of 20-125 K at an 80 kV
excitation voltage. Images were analyzed using the
SIS Megaview II Image Capture system
(Olympus, Germany).
Effects of α 2M and Hp on the sedimentation
properties of substrate proteins
At the endpoints of the aggregation reactions,
samples of Aβ , Calc and I59T, with or without
α2M or Hp, were centrifuged for 30 min at 10,000
g. The supernatant was removed and the pellet
resuspended and subsequently washed repeatedly
in PBS. Aβ samples were analyzed by 15% SDS
PAGE and subsequent immunoblotting using
WO2
(an
anti-Aβ monoclonal
antibody).
Electrophoretic blotting of Calc was not performed
because its low molecular mass (3418 kDa) results
in a very low efficiency of transfer to the
membrane. Instead, Calc samples were analyzed
by spotting them directly onto a nitrocellulose
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membrane (Pall, FL, USA) before blocking with
HDC/PBS and probing with a rabbit anti-Calc
antibody (Abcam, Sydney, Australia).
I59T
samples were analyzed by 10% SDS PAGE and
subsequent immunoblotting using a polyclonal
rabbit anti-lysozyme antibody (Washington
Biotechnology, Simpsonville, MD, USA). Bound
antibodies were detected with either HRPconjugated sheep anti-mouse IgG or sheep antirabbit IgG antibodies (Silenus, Melbourne,
Australia)
followed
by
enhanced
chemiluminescence (ECL) with Supersignal West
Pico Chemiluminescent Substrate (Pierce, IL,
USA).
Immuno dot blots
Samples of Aβ (1 µg) , taken at various time
points during fibril formation and stored frozen at
- 20 oC were spotted on to nitrocellulose
membranes (Pall, FL, USA) and allowed to air
dry. The membranes were then blocked with 1%
(w/v) heat denatured casein in PBS (HDC/PBS)
and incubated for 2 h at 37 oC in PBS containing
10 µg/ml α2M or Hp, or control protein GST,
before being washed with PBS. Bound α2M and
Hp were detected using specific rabbit polyclonal
antibodies (Sigma and DAKO, respectively). A
rabbit anti-GST antibody (Chemicon, Melbourne,
Australia) was used to detect any bound control
protein. Bound primary antibodies were detected
as described above.
Sandwich ELISA
To determine if stable complexes are formed
between α2M or Hp and amyloid-forming
peptides, we sampled aggregation reactions
containing sufficient α2M or Hp to inhibit most of
the protein aggregation that is observed in their
absence (i.e. molar ratios of α2M/Hp:Aβ/I59T =
1:10, α2M/Hp:Calc = 1:15). These samples
contained almost all the substrate protein in the
soluble fraction (see immunoblot analyses of
corresponding samples in Figure 4A-C) and were
centrifuged at 13,000 g for 10 min before analysis
to remove any traces of insoluble materials.
Samples were taken at a time corresponding to the
mid-point of the aggregation process in the
absence of the chaperones, and were subsequently
analyzed by a sandwich ELISA. Aggregation

reactions were initiated as above using molar
ratios of α2M/Hp to substrate of 1:10 (Aβ and
I59T) or 1:15 (Calc and ccβw). In the cases of Aβ
and ccβw, the peptides were biotinylated using
standard methods prior to the aggregation reaction.
This modification did not affect the ability of the
peptides to form thio T positive aggregates (data
not shown). 96 well plates (Greiner Bio-one,
Sydney, Australia) were coated with 10 µg/ml of
either anti-α2M (Dako, Glostrup, Denmark) or
anti-Hp (Sigma, Sydney, Australia) antibodies
raised in rabbit and then blocked with 1% (w/v)
BSA in PBS. Samples of aggregation mixtures
(with or without α2M or Hp), were next added to
the wells at a concentration of 50 µg/ml of
amyloid forming protein. In other wells, solutions
of α2M or Hp alone (at the same final
concentrations as in the corresponding mixtures)
were added. Next, a mixture of streptavidin and
biotinylated-HRP (each at 2.5 µg/ml in 1% (w/v)
heat-denatured casein in PBS) was used to detect
bound Aβ or ccβw. Antibody detection of bound
Calc was performed as described above. Bound
I59T was detected using a mouse monoclonal antilysozyme antibody (Serotec, UK), followed by
HRP-conjugated sheep anti-mouse IgG. Finally,
plates were washed 3 times in PBS containing 0.1
% (v/v) Triton X-100 and then in PBS alone
before being developed using 2.5 mg/ml ophenylenediamine dihydrochloride and 0.03%
(w/v) H2O2 in 0.05 M citric acid, 0.1M NaHPO4
(pH 5) as substrate. The absorbance was measured
at 490 nm in a SpectraMax Plus 384 microplate
reader (Molecular Devices, USA). Negative
controls included the use of an antibody that has
no specificity to the proteins under investigation
(rabbit anti-DNP), and wells incubated with only
the mixture of streptavidin and biotinylated HRP
described above.
Results

α 2M and Hp inhibit fibril formation in vitro
In the absence of α2M and Hp, aggregation of all
the substrates tested showed a lag phase followed
by a rapid growth phase, which eventually
approached a plateau. The lag phases were
somewhat
variable
between
individual
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experiments but ranged from approximately 25-50,
5-20, 20-30 and 75-150 min for Aβ, ccβw, Calc
and I59T, respectively (see Figures 1A-D & 2AD). The addition of α2M to all fibril-forming
reactions produced a dose-dependent decrease in
Thio T positive aggregation in each case (Figure
1). In the case of I59T, for which aggregation was
followed by measuring absorbance at 500 nm,
analysis of endpoint samples confirmed that Thio
T fluorescence was reproducibly suppressed by
α2M (Figure 1E; α2M:I59T = 1:10). α2M extended
the lag phase in all reactions even though the final
level of aggregation was not always greatly
reduced (Figure 2A-D); this observation suggests
that α2M affects the nucleation step in the
aggregation reaction. A sub-stoichiometric ratio of
α2M:substrate was sufficient to inhibit aggregation
almost completely in each case (1:10 for Aβ and
I59T; 1:15 for ccβw and Calc). Hp also inhibited
the aggregation of all substrates tested in a dosedependent manner (Figure 2). Like α2M, at
concentrations where aggregation was not
completely suppressed, Hp extended the lag phase
significantly (Figure 2A-D). As with α2M, a substoichiometric ratio of Hp:substrate was sufficient
to inhibit almost completely all the Thio T positive
aggregation (1:10 for Aβ and I59T, 1:15 for ccβw
and Calc). In the case of I59T, endpoint Thio T
analysis confirmed that Hp substantially
suppressed Thio T fluorescence (Figure 2E;
Hp:I59T = 1:10). The presence of the control
protein BSA in the amyloid forming reactions had
no effect on aggregation for any of the substrates
tested (supplemental Fig. S1). In addition, when
incubated alone, neither Hp nor α2M generated
Thio T-reactive material under any of the
conditions tested (data not shown). When
complexed with hemoglobin, Hp retained the
ability to inhibit amyloid formation by Aβ and
ccβw, however this ability was less than that of
uncomplexed Hp (supplemental Fig. S2).
To verify that both α2M and Hp can inhibit the
formation of amyloid fibrils we examined protein
aggregation mixtures with and without α2M and
Hp using transmission electron microscopy
(TEM). In the absence of either α2M or Hp,
samples from all substrate proteins tested
contained fibrillar aggregates (Figure 3). Addition
of α2M to the Calc and I59T aggregation reactions

substantially inhibited the formation of fibrils, and
only a small number of short fibril-like structures
were observed in 1:10 α2M:Aβ and 1:15 α2M:ccβw
samples (Figure 3). The addition of Hp to Aβ,
ccβw and I59T aggregation reactions (at ratios of
Hp:substrate of 1:10, 1:15 & 1:10, respectively)
significantly inhibited the formation of fibrils;
only small amounts of amorphous material were
detected in these samples (Figure 3). However,
although a 1:15 ratio of Hp:Calc substantially
reduced Thio T fluorescence (Figure 2C), a variety
of short fibril-like structures were detected in these
cases.
Both α 2M and Hp affect the sedimentation
properties of amyloid forming proteins
α2M and Hp were added at various concentrations
to Aβ, Calc and I59T fibril formation reactions
and at the end of the time course the samples were
centrifuged to obtain supernatant and pellet
fractions. The Aβ and I59T samples were then
analyzed by immunoblotting. Due to the low
efficiency with which relatively small peptides are
electrophoretically transferred to nitrocellulose,
Calc samples were analyzed by immuno dot
blotting. ccβw samples could not be analysed in
either of these ways because there are no suitable
commercially available antibodies; furthermore, it
stains very poorly with Coomassie blue making
SDS PAGE analysis difficult. In the absence of
α2M or Hp, Aβ was found exclusively in the pellet
fraction and consisted of high molecular mass
aggregates (Figure 4A; Aβ alone). When α2M was
added to the reaction to give a 1:10 molar ratio of
α2M:Aβ, all of the Aβ was found in the
supernatant fraction; subsequent decreases in the
amount of α2M added to the reaction resulted in a
progressive shift of Aβ from the supernatant
fraction to the pellet fraction (Figure 4Ai).
Similarly, the addition of a 1:10 molar ratio of
Hp:Aβ resulted in the presence of Aβ in the
supernatant fraction; as the amount of Hp added
was decreased, progressively more Aβ was found
in the pellet fraction (Figure 4Aii). In the absence
of either α2M or Hp, Calc was detected only in the
pellet fraction (Figure 4B). In contrast, when α2M
was present in the reaction (at α2M:Calc = 1:15),
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most of the Calc was detected in the supernatant
fraction and the proportion of Calc in the pellet
fraction increased as the amount of α2M in the
reaction decreased (Figure 4B). Similarly, in the
presence of Hp (Hp:Calc = 1:15) all of the Calc
was detected in the supernatant fraction and
subsequent decreases in Hp resulted in more Calc
detected in the pellet fraction (Figure 4B). In the
absence of either α2M or Hp, I59T was detected
only in the pellet fraction (Figure 4C). In contrast,
when incubated in the presence of either α2M or
Hp (α2M/Hp:I59T = 1:10), I59T was detected
primarily in the supernatant fraction (Figure 4C).

timepoint, nor to the final timepoint samples
(Figure 6). There was also no detectable binding of
the control protein GST to any of the Aβ samples
tested (data not shown). In addition when assayed
by immuno dot blotting there was no detectable
binding of α2M or Hp to species present at any
time in the aggregation reactions of any of the
other substrates tested (data not shown). The
reasons for this observation are unclear but might
result from the interacting species being present at
levels too low to detect using this assay procedure.
We therefore used a sandwich ELISA method to
demonstrate the formation of α2M/Hp-substrate
protein complexes in the aggregation reactions.

α 2M and Hp do not influence fibril elongation or
disrupt pre-formed fibrils
To determine whether α2M and Hp inhibit fibril
formation by affecting the nucleation and/or fibril
elongation phases, α2M or Hp was added either at
the beginning of the reaction (0 min) or mid-way
through the elongation phase of aggregating Aβ,
ccβw, calc or I59T (at 150, 50, 75 and 100 min,
respectively). Addition of either α2M or Hp at zero
time (Hp/α2M:substrate = 1:10) resulted in almost
total inhibition of aggregation over the entire
reaction (Figure 5). In contrast, when the same
molar ratios of α2M or Hp were added to the
reactions during the elongation phase, there were
little or no measurable effects on aggregation
(Figure 5A and 5B). It was also shown that, over a
500 min time frame, the addition of α2M or Hp to
pre-formed fibrils of Aβ, Calc or ccβw had no
measurable effect on the integrity of the fibrils
(supplemental Fig. S3).

α 2M and Hp bind transient prefibrillar species
on the Aβ amyloid formation pathway
Samples taken at various points in time during Aβ
fibril formation reactions in the absence of Hp and
α2M were spotted on to nitrocellulose membranes.
Maximum binding of both α2M and Hp was
detected to Aβ species present in samples taken
0.5 and 1 hour after the initiation of aggregation
(Figure 6). These times correspond to the
transition between the lag and growth phases
(Figure 6). α2M and Hp were not found to bind to
the native substrates present in samples at the zero

α 2M and Hp form stable complexes with species
on the amyloid forming pathway
A sandwich ELISA was used to determine whether
or not α2M and Hp form stable complexes with
substrate proteins during aggregation reactions.
We observed a statistically significant increase in
absorbance (p < 0.05) when aggregation mixtures
of α2M and Aβ, ccβw or calc were compared with
samples containing substrate alone and with
negative controls (Figure 7A). We were unable to
detect a corresponding increase in absorbance for
samples taken from mixtures of α2M and I59T
(Figure 7A), Samples from aggregation mixtures
containing Hp and any of the four substrate
proteins we studied also gave significantly higher
absorbances than corresponding samples of
aggregation reactions containing substrate alone,
or of negative controls (p < 0.05; Figure 7B).
Discussion
Previous work has indicated that α2M can inhibit
the in vitro formation of amyloid fibrils by Aβ (6).
In addition, both α2M and Hp have been found
associated with Aβ plaques in Alzheimer’s
patients (20,27). The results presented here
demonstrate that both α2M and Hp can potently
inhibit the in vitro formation of amyloid fibrils by
a diverse panel of proteins under physiologically
relevant conditions. For Aβ, ccβw and Calc these
effects were observed at 37 oC and pH 7.5. In the
case of Aβ, fibril formation was induced by the
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addition of 100 µM Cu2+ (30), the concentration
that Cu2+ can reach in the normal human neocortex
(31); in the neuropil of the cortical and accessory
basal nuclei of the amygdala of Alzheimer
diseased brains it has been reported to reach
several times this level (32). Hp and α2M both
exert similar activity under the non-physiological
conditions used here to form fibrils from I59T (60
o
C, pH 5). We have previously shown that both
α2M and Hp remain fully functionally active at
this elevated temperature and do not aggregate
even when incubated at 60 oC for extended periods
(10,11). These data suggest that the antiamyloidogenic activities of Hp and α2M are not
dependent on the identity of the polypeptide
substrate or the conditions under which it is
incubated. This activity was found to be specific
since similar levels of the control protein BSA
(molar ratio of BSA:substrate = 1:10) had no
detectable effect on the aggregation of any of the
substrates tested here (supplemental Fig. S1). Hp
retained the ability to inhibit amyloid formation
even when complexed with hemoglobin, although
this activity was reduced when compared to that of
uncomplexed Hp. This is consistent with a
previous report that complexation with Hb reduces
but does not abolish the ability of Hp to inhibit the
amorphous aggregation of protein (33). We have
previously reported that activation of α2M by
interaction with trypsin abolished its ability to
inhibit the amorphous heat-induced aggregation of
two globular proteins (11). The effects of protease
activation on the ability of α2M to inhibit amyloid
formation are complex and are influenced by the
facts that the bound protease remains catalytically
active and sterically accessible to small protein
substrates of less than 8 kDa in mass (but not to
those of greater mass) (34). The consequences of
this for the anti-amyloidogenic activity of α2M
will be dealt with in detail in a separate report.

experiments, lower levels of α2M and Hp
(Hp/α2M:substrate of 1:500 to 1:30, Figures 1 &
2), failed to reduce the final level of protein
aggregation. However, in these cases the lag phase
of the reaction was significantly extended. This
suggests that when present at low levels, the
effects of α2M and Hp are eventually
overwhelmed, but that even under these conditions
they can delay nucleation and thus defer the
subsequent elongation phase. Both α2M and Hp
were more effective at suppressing aggregation of
amyloidogenic substrates when added at the
initiation of the reaction rather than when added
during the elongation phase (Figure 5). This
finding suggests that both proteins exert their
effects on amyloid formation primarily by
interacting with species on the amyloid-forming
pathway that are more abundant prior to fibril
elongation. Together with the observation that
both α2M and Hp effectively extend the lag phase
even when present at low concentrations, these
data suggest that they interact with protein species
that are either functional nuclei or their precursors.
Immuno dot blot analyses show α2M and Hp bind
to transient species of Aβ present early in the
aggregation time course (Figure 6). α2M and Hp
appear not to bind to samples taken before the start
of the reaction or those taken at the end of the
reaction (Figure 6). This result demonstrates that,
at least in the case of Aβ, α2M and Hp do not
detectably bind to the native monomer or to
mature fibrils formed from them. It was also
shown that, at least over a 500 min co-incubation,
α2M and Hp did not affect the stability of mature
fibrils formed from Aβ, Calc or ccβw
(supplemental Fig. S3). These data are all
consistent with the idea that both α2M and Hp
specifically bind to species that are particularly
abundant during fibril nucleation.

In all cases examined in this study, significantly
sub-stoichiometric molar ratios of α2M or Hp to
substrate (from 1:10 to 1:15) were enough to
substantially inhibit the formation of amyloid
fibrils as judged by thioflavin T fluorescence, light
scattering and TEM (Figures 1-3). When present at
sufficient levels, both α2M and Hp reduced the
sedimentability of species present in aggregation
reactions of Aβ, Calc and I59T (Figure 4). In some

The above suggests that α2M and Hp form
complexes with conformations of substrate
proteins which are intermediate on the amyloid
forming pathway; these complexes could be either
short lived or more persistent. Analysis of
aggregation mixtures by sandwich ELISA strongly
suggest that stable complexes are formed between
Hp and all four substrate proteins tested. The fact
that complexes between α2M and I59T were not
detected suggests that the interacting species are
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present in this case at very low levels.
Nevertheless, it seems likely that α2M binds to
aggregation-prone prefibrillar species formed early
in aggregation reactions.
Collectively, the results indicate that substoichiometric levels of α2M and Hp effectively
suppress amyloid fibril formation in vitro by a
broad range of protein substrates. The data suggest
that both α2M and Hp exert this activity by
interacting with one or more transient species on
the amyloid forming pathway that is populated
most heavily before fibril elongation begins. This
conclusion is consistent with the hypothesis that
like clusterin, α2M and Hp bind to species sharing
common structural features present during
amyloid formation of a range of substrates (9).
The interactions between α2M/Hp and substrate
proteins appear to be stable and act to preserve the
solubility of the substrates. The current findings
are in accord with previous work demonstrating
that both α2M and Hp have chaperone activity
similar to that of the small heat shock proteins.
Both α2M and Hp inhibit the formation of
amorphous aggregation by a range of proteins by
forming soluble complexes (10,11). Together with
previous findings (8-11,35), the work presented
here suggests that clusterin, α2M and Hp make up
a small family of extracellular chaperones that
may be an important part of an in vivo quality
control system for extracellular proteins. It has
been proposed that extracellular chaperones
respond to misfolded or aggregating proteins in
extracellular space by binding to exposed
hydrophobic regions, maintaining the solubility of
the substrate and promoting its removal from the
extracellular space via receptor mediated

endocytosis. This proposal is fully consistent with
all the data presented here, and with data that show
that the removal of radiolabelled Aβ from mouse
brain is significantly inhibited by the LDL family
inhibitor RAP and antibodies against the α2M
receptor (LRP-1) and α2M (36). This hypothesis is
also supported by the demonstration that, when
complexed with clusterin, the rate of clearance of
Aβ1-42 from the mouse brain (across the blood
brain barrier into plasma) is increased by more
than 80% and that this transport is significantly
inhibited by anti-megalin antibodies (37).
Clusterin (8,9), and both α2M and Hp (this study),
appear to inhibit amyloid formation and maintain
substrate protein solubility by interacting with
prefibrillar species. These extracellular chaperones
are also known to potently inhibit amorphous
aggregation of proteins (10,11,35,38,39). We
suggest that this small family of chaperones is
likely to be an important part of a system that
defends the human body against inappropriate
extracellular protein aggregation, which can be
either amorphous or amyloid in character.
Presumably, it is only during exceptional
circumstances (e.g. the result of a mutation, agerelated loss-of-function, or acute stress) that this
system of defence is overwhelmed and disease
results. The increasing number of known
extracellular deposition disorders, which include
conditions such as Alzheimer’s disease and Type
II diabetes, has made the need for understanding
the mechanisms controlling extracellular protein
folding of major importance to modern health
care. Greater understanding of these processes will
ultimately lead to the development of new
therapeutic strategies.
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FIGURE LEGENDS
Figure 1 α 2M suppresses the aggregation of amyloidogenic proteins. Samples of Aβ (10 µM), ccβw
(60 µM), Calc (50 µM), and I59T (6.8 µM) were incubated as described in Experimental Procedures,
and amyloid formation monitored by in situ measurements of Thio T fluorescence (A-C), or for I59T by
measuring turbidity (absorbance at 500 nm; D) and endpoint measurement of Thio T fluorescence
emission spectra (E). In A-E, the open circles represent data for the proteins aggregating in the absence
of α2M; the molar ratio of α2M to substrate protein is indicated next to the variously shaded circles on
each panel. In (E), the spectrum of Thio T alone (in the absence of any protein) is also shown. The data
points shown are representative of at least three 3 independent experiments.
Figure 2 Hp suppresses the aggregation of amyloidogenic proteins. The experiments with Aβ (10
µM), ccβw (60 µM), Calc (50 µM), and I59T (6.8 µM) are analogous to those described for α2M in the
legend for Figure 1.
Figure 3 α 2M and Hp suppress the formation of fibrillar structures. TEM images of samples taken at
the conclusion of aggregation reactions containing substrate proteins either alone or in the presence of
α2M or Hp (as indicated above the panels). The molar ratio of Hp/α2M:substrate used was 1:10 for
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Aβ and Ι59Τ, and 1:15 for ccβw and Calc. In all cases the results shown are representative of two or
more individual experiments. The scale bar in the lower right panel applies to all TEM images shown
here and represents 500 nm.
Figure 4 α2M and Hp form stable complexes with Aβ and maintain its solubility. (A) Aβ immunoblot
showing supernatant (S) and pellet (P) fractions prepared by centrifugation of aggregation reactions
containing various ratios of α2M/Hp:Aβ (indicated above the corresponding lanes). (B) Images of
immuno dot blots showing supernatant (S) and pellet (P) fractions resulting from centrifugation of
samples from aggregation reactions containing various ratios of α2M/Hp:Calc (indicated above the
corresponding spots). (C) I59T immunoblot showing supernatant (S) and pellet (P) fractions prepared
by centrifugation of samples from aggregation reactions containing I59T alone or a 1:10 ratio of
α2M/Hp:I59T (indicated above the corresponding lanes). The results shown are representative of at least
2 independent experiments.
Figure 5 α2M and Hp are most effective when added at the start of the aggregation reaction.
Samples of Aβ (10 µM), ccβw (60 µM), Calc (50 µM) and I59T (6.8 µM) were incubated as described
in Experimental Procedures and amyloid formation was monitored by in situ measurements of Thio T
fluorescence (i-iii), or for I59T by measuring turbidity (iv). 1:10 ratios of (A) α2M:substrate or (B)
Hp:substrate were added at either time zero (grey diamonds) or at the mid-point of the elongation phase
(grey circles; addition of α2M and Hp indicated by arrows). Each symbol represents an individual
measurement and the results shown are representative of at least 2 independent experiments.
Figure 6 α 2M and Hp bind transient species early in Aβ fibril formation. Results of immuno dot blot
assay measuring the binding of α2M and Hp to protein species present at different times during Aβ
fibril formation. Aβ (10 µM) was incubated as described in Experimental Procedures and aliquots taken
at various time points. The times at which individual samples were taken are indicated above the
images and the Thio T fluorescence of each aliquot was measured. Aβ (∼ 1 µg) from each sample was
then spotted onto nitrocellulose and the membrane blocked and subsequently incubated with 10 µg/ml
of either α2M or Hp. The presence of α2M and Hp was detected using rabbit anti-α2M and anti-Hp
antibodies.
Figure 7 α2M and Hp form stable complexes with amyloid forming proteins. Histograms showing the
results of sandwich ELISA detecting complexes formed between α2M/Hp and amyloid forming
proteins. Samples taken from aggregation reactions at times corresponding to the midpoint of the
elongation phase (in the absence of α2M/Hp) were analyzed by ELISA using plate bound anti-α2M (A)
or anti-Hp (B) antibodies to capture α2M and Hp respectively. Bound amyloid forming proteins were
subsequently detected using specific antibodies, or (in the case of biotinylated Aβ and ccβw) a
streptavidin/biotinylated-horseradish (b-HRP) peroxidase complex. Non-specific binding of substrate
was tested using samples taken from aggregation reactions of substrate alone at the same time points.
For biotinylated Aβ and ccβw, the negative controls were anti-α2M/anti-Hp coated wells incubated with
only streptavidin/biotinylated-horseradish peroxidase complex. For Calc and I59T, the negative controls
were provided by substituting appropriate antibodies of irrelevant specificity for the anti-Calc or antilysozyme antibodies (see Experimental Procedures for details). Values shown represent the mean of at
least 3 wells and error bars represent standard error. Significant differences to controls are indicated by
* (Student’s t-test; p < 0.05). Results shown are representative of at least 2 independent experiments.
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Supplementary Figure S1 Control protein BSA does not inhibit aggregation of amyloid forming proteins. Aβ
(10 µM), ccβw (60 µM), Calc (50 µM), and I59T (6.8 µM) were incubated as described in Experimental
Procedures and amyloid formation monitored by in situ measurements of Thio T fluorescence (A-C), or for I59T
by measuring turbidity (absorbance at 500 nm; D). In A-E, the empty circles represent data for the protein
aggregating in the absence of BSA; when present, the molar ratio of BSA to substrate protein is 1:10. Data points
shown are individual measurements and are representative of at least three 3 independent experiments.
Supplemental Figure S2 Haptoglobin suppression of amyloid forming protein aggregation is affected

by binding of Hb. Aβ (10 µM) and ccβw (60 µM) were incubated as described in Experimental
Procedures and amyloid formation monitored by in situ measurements of Thio T fluorescence. The
empty circles represent data for the protein aggregating in the absence of Hp, while shaded symbols
represent amyloid forming protein incubated with Hp or a preincubated equimolar mixture of Hp and
Hb (as indicated on panels). In all cases when present, the molar ratio of Hp to Aβ and ccβw is 1:10 and
1:15, respectively. Data points shown are individual measurements and are representative of at least
three 3 independent experiments.
Supplemental Figure S3 α 2M and Hp do not dissociate mature amyloid fibrils. (A) Histogram showing

the end point Thio T fluorescence of mature fibrils incubated with either α2M or Hp (as described in
Experimental Procedures) for 500 minutes at 37oC in PBS. (B) Protein content of insoluble material
retrieved by centrifugation at the endpoint of mixtures containing mature fibrils and either α2M or Hp
(molar ratios as above). Values shown represent the mean of at least 3 determinations and error bars
represent standard error. Results shown are representative of at least 2 independent experiments.
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